Second time around


Second time around

26.11.2015 - Guido Rasi has once again taken office as Executive Director of the European Medicines Agency’s Management Board on 16 November.

Rasi already held this position from 2011 until 2014, when he was forced to step down due to irregularities during the selection process. 

The professor of microbiology was Director-General of the Italian Medicines Agency from 2008 to 2011. Before that, he was the Director of the Institute of Molecular Medicine of the National Research Council in Rome. For twelve years, he worked as a physician in hospital, research and private practice before switching to the Institute for Experimental Medicine of Italy’s National Research Council.

Rasi has authored more than 100 scientific publications.


22.09.2015 Belgian commercial-stage MDx company Biocartis has appointed Hilde Windels as Deputy CEO.

© Biocartis

Windels previously held the role of CFO at Biocartis, a role she now hands over to corporate financier Ewoud Welten. Before joining Biocartis in 2008, Windels was CFO at Pronota, and before that, at Seps Pharma and Devgen.

She is on the board of directors at Erytech and at the life sciences research institute VIB. She was on the board of biotech association Flanders Bio until 2014.


18.09.2015 Autifony Therapeutics Ltd, a pioneering developer of pharmaceutical treatments for hearing disorders, has named John Hutchison as its new Chief Medical Officer. Hutchison will replace erstwhile CMO Peter Harris, who is retiring at the end of September.

© Autifony

Hutchison, who holds a PhD in Neurobiology by the University of Liverpool, joins Autifony from Pfizer, where he was Chief Medical Officer and VP of Clinical Research at Pfizer Neusentis in the UK. Due to his long experience in clinical drug development in both big pharma and the biotech sector he will take over the lead of Autifony’s growing clinical development team that will oversee the evaluation of two different candidate drugs in multiple clinical trials by the end of the year.


16.09.2015 Oxford-based oncology drug developer Physiomics has appointed Mark Middleton to its Scientific Advisory Board. Middleton is Professor of Experimental Cancer Medicine in the Department of Oncology of the University of Oxford.

© Physiomics

He is the Lead Cancer Clinician for the Oxford University Hospitals NHS Trust and deputy director of the Cancer Research UK Oxford Centre. He directs the EPCTU and the Cancer Theme of the NIHR Biomedical Research Centre, and leads several clinical trials in the national portfolio. 

Middleton is a member of the International Melanoma Working Group and of the NCRI Melanoma Clinical Studies Group.


14.09.2015 Swedish cancer vaccine play Immunicum AB has hired Linda Barkemo as Director Clinical Operations.

© Immunicum AB

Barkemo comes from a position as Regional Director Northern Europe at CRO Clintec. Previously, the trained nurse was Clinical Trial Manager at Artimplant and was responsible for clinical studies at AstraZeneca and Pfizer. 


10.09.2015 Recently founded EIT Health has found its CEO: Sylvie Bove is taking over the lead of the European healthcare initiative in September.

© EIT Health

Bove has 20 years of experience as a business executive in the life sciences. Originally from France, she has spent many years in Scandinavia at companies such as Coloplast and Ferring Pharmaceuticals. She contributed to the foundation of the Copenhagen Healthtech Cluster. For the last three years, she also held the role of Innovation Officer at Lund University. 

At EIT Health, Bove will take over from Roche’s Ursula Redeker who served as interim CEO since October 2014. 


07.09.2015 In mid-September, Sean Bohen is joining AstraZeneca as Executive VP of Global Medicines Development and CMO. He will be responsible for late-stage development of small molecule meds and biologics.

© AstraZeneca

Previously, the drug development expert with a doctorate in biochemistry and a medical degree served as Senior VP of Early Development at Genentech. Here, he also held a number of positions in early and late-stage development. Before joining Genentech, Bohen was a clinical instructor in oncology at Stanford University School of Medicine, a research associate at the Howard Hughes Medical Institute and a postdoctoral fellow at the National Cancer Institute.


17.08.2015 George Gunn is the newest member of the board of Pharmaq Holding AS, a Norway-based leader in pharmaceuticals for the aquaculture industry.

© Pharmaq

Gunn has an extensive background in animal health and has recently retired from Novartis AG. At Novartis, the born Scotsman started in 2003 as Head of Animal Health, North America. He went on to head Novartis Animal Health from 2004 until 2015, when the division was sold to Elanco. Prior to joining Novartis, Gunn served as President of Pharmacia Animal Health for three years.

Gunn received the Honorary Degree of Doctor of Veterinary Medicine and Surgery from the University of Edinburgh in 2008. This year, he received a Lifetime Achievement award from the International Federation of Animal Health for his services to the animal health sector.


26.08.2015 In August, Thomas Bachmann has taken over the role of CEO at Eppendorf Group. Bachmann has been a member of the Supervisory Board of the German laboratory product and service provider since 2013.

© Eppendorf AG

Bachmann has been active in the Life Sciences for ten years. Before switching to Eppendorf, he was President of the Bruker BioSpin Group. Prior to that, he was responsible for the Switzerland-based Tecan Group.


06.08.2015 Cancer immunotherapy play Rigontec GmbH has appointed J. Donald deBethizy as Chairman of the Board of Directors. He replaces Gunther Hartmann, who co-founded the Bonn-based company in early 2014 and will remain on the board.

© Rigontec GmbH

deBethizy brings long years of biotech and R&D experience to the spin-out of Bonn University. He is already serving on the supervisory boards of arGEN-X NV, Newron Pharmaceuticals SPA, Serendex Pharmaceuticals and Noxxon Pharma AG. He is also President of White City Consulting ApS in Denmark.

Previously, deBethizy, who holds MS and PhD degrees in toxicology from Utah State University and a BS in biology from the University of Maryland, served as President and CEO of Santaris Pharma A/S and as Executive Chairman of Contera Pharma. He was also co-founder and CEO of US biotechnology company Targacept Inc.


17.08.2015 While CEO Matthias Schroff and CFO Jörg Petraß have resigned their positions at Mologen AG, the new CEO is already waiting in the wings. In November 2015, Mariola Söhngen will be taking over the reins of the Berlin-based drug developer.

© Paion AG

Söhngen has held the position of Chief Medical Officer of Paion AG, which she also co-founded. At the specialty pharma company, which is listed on Frankfurt Stock Exchange, she was responsible for phase I to IV clinical development, regulatory and approval issues, pharmaceutical drug safety, quality assurance, project management, Human Resources, Intellectual Property as well as preclinical research and development.

Vorherige Seite3/30Nächste Seite

Current issue

All issues


All videos

Product of the week


Stock list

All quotes


  • EVOCUTIS (UK)0.12 GBP33.33%
  • EPIGENOMICS (D)2.65 EUR17.26%


  • THERAMETRICS (CH)0.04 CHF-20.00%
  • SERODUS (N)2.18 NOK-18.35%
  • DEINOVE (F)5.14 EUR-17.63%


  • PLETHORA (UK)5.50 GBP76.3%
  • CELLECTIS (F)31.65 EUR41.1%


  • EPIGENOMICS (D)2.65 EUR-39.6%
  • DEINOVE (F)5.14 EUR-21.3%


  • KARO BIO (S)37.90 SEK5314.3%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • GALAPAGOS (B)46.60 EUR260.1%


  • BIOTEST (D)15.31 EUR-81.0%
  • NEOVACS (F)0.80 EUR-76.5%

No liability assumed, Date: 27.11.2015


All Events


Strasbourg (F)

BioFIT 2015